U.S. health regulators are warning consumers not to use more than two dozen varieties of over-the-counter eyedrops because of the risk of infections that could lead to blindness.
The Food and Drug Administration advisory applies to lubricating drops sold by six companies, including CVS Health, Target, Rite Aid and Cardinal Health. Consumers should stop using the products immediately and avoid purchasing any that remain on pharmacy and store shelves, the FDA said in a statement Friday.
The agency asked the companies to recall their products last week, because FDA inspectors found unsanitary conditions and bacteria at the facility producing the drops. The FDA did not disclose the location of the factory or when it was inspected.
No injuries related to the products had been reported at the time of the announcement, but the FDA encouraged doctors and patients to submit cases through the agency’s online reporting system.
Earlier this year, federal officials linked an outbreak of drug-resistant bacteria to eyedrops from two companies, EzriCare and Delsam Pharma. More than 80 people in the U.S. tested positive for eye infections from the rare bacterial strain, according to the most recent update from the Centers for Disease Control and Prevention.
After the products were recalled in February, health inspectors visited the manufacturing plant in India that made the eyedrops and uncovered problems with how they were made and tested, including inadequate sterility measures.
It's Friday at long last. Jill and Carlo cover the latest on Omicron, including a possible superspreader event in NYC. Plus, previewing the November jobs report, a new Zoom feature no one asked for, and when it's no longer a good idea to eat Thanksgiving leftovers.
Three cases of the new omicron COVID-19 variant have been confirmed in the U.S. Cheddar speaks with global infection disease specialist Dr. Rajeev Fernando on how to prepare for a possible new coronavirus wave.
In 2015, 193 parties signed the Paris Agreement. In doing so, they agreed to pursue efforts to limit the average global temperature increase to 1.5° Celsius - or 2.7 degrees Fahrenheit -above pre-industrial levels. To be clear, our planet is already 1.1 degrees hotter than it was 150 years ago. But most scientists agree that an increase of just .4 more degrees will drastically change the world. However, it would continue to be livable. Things do get murky, though, as the projections increase above that.
Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to break down how people can protect themselves and family amid the uncertainty of the new Omicron COVID-19 variant. Caudle emphasized the importance of getting vaccinated against COVID-19 with so much still uncertain about the pandemic. "We have to remember delta variant is still here in the United States," she said. "We're still losing too many people every single day to this virus."
Jill and Carlo discuss what appears to be the beginning of the end of Roe v. Wade, another victim dies following the school shooting in Michigan, Omicron in the U.S., Trump's Covid chronology and more.
Was it a coincidence that the omicron coronavirus variant evolved in a region with low vaccination rates? Cheddar speaks with epidemiologist Dr. Eric Feigl-Ding on the topic.
Astra founder, chairman, and CEO Chris Kemp spoke to Cheddar's Kristen Scholer about his company's first successful launch into orbit last month, becoming the fastest space company to reach orbit using a privately developed liquid-fueled rocket. He also noted that the company's priority is to "improve life on Earth from space" by rapidly increasing the number of low-orbiting satellites to do everything from connecting people to monitoring weather patterns.
Stocks closed at session lows Wednesday as investors grew skittish over the first reported case of the COVID-19 omicron variant in California. Josh Sailar, Partner at Blue Zone Wealth Advisors, joins Cheddar News' Closing Bell to discuss investor worry over the new variant, the Fed dropping the word 'transitory' to describe inflation and potentially speeding up their asset tapering timeline, 2022 predictions, and more.
